Yes, leprosy is still very much a thing. In 2024, 172,717 new cases were diagnosed across 188 countries. While the disease has been largely eliminated in wealthy nations, it remains a significant public health challenge in parts of Asia, Africa, and South America. It is curable with antibiotics, but late diagnosis still leads to permanent disability for thousands of people each year.
Where Leprosy Persists Today
The World Health Organization tracks leprosy reports from nearly every country on Earth. Of the roughly 173,000 new cases detected in 2024, about 40% were in women and 5.4% were in children, a sign that transmission is still actively occurring in communities rather than simply being diagnosed in people who were infected long ago. India, Brazil, and Indonesia consistently report the highest numbers.
Even the United States sees cases each year, primarily in the southern states bordering the Gulf of Mexico, where the disease has been present at low levels since at least the 1700s. Cases also appear in people who have spent time in countries where leprosy is more common. The numbers in the U.S. are small enough that most doctors will never encounter a case in their careers, but the disease has not disappeared.
How It Spreads (and Why It’s Hard to Catch)
Leprosy spreads through respiratory droplets when someone with an untreated infection coughs or sneezes. But unlike the flu or COVID, casual contact is not enough. You would need prolonged, close contact with an untreated person over many months to become infected. Brief encounters, handshakes, sitting next to someone on a bus: none of these pose a realistic risk.
Most people’s immune systems can fight off the bacterium on their own. The exact percentage with natural immunity isn’t firmly established, but researchers have long noted that even among household contacts of untreated patients, the majority never develop the disease. The bacterium itself, Mycobacterium leprae, is one of the slowest-growing pathogens known. Its incubation period averages about five years, but symptoms can take as long as 20 years to appear, which makes tracing exactly when and where someone was exposed extremely difficult.
Armadillos Are a Surprising Source
Nine-banded armadillos carry the same bacterium that causes leprosy in humans, and they are now considered a confirmed source of transmission in the Americas. These animals range from the southern United States down through Latin America to northern Argentina. The highest risk comes from direct contact with an infected armadillo’s blood or tissue, which means people who hunt, handle, or eat armadillos face the greatest exposure. The CDC has noted that at least two separate introductions of the bacterium into armadillo populations have occurred in the U.S., and the geographic range of this animal-to-human transmission pathway appears to be expanding.
What Leprosy Looks and Feels Like
The disease primarily targets the skin and peripheral nerves. Early signs often include discolored or lighter patches of skin that have lost sensation. You might not feel pain, temperature, or touch in those areas. This numbness is actually one of the most dangerous features of the disease, because injuries to affected hands or feet go unnoticed and untreated, leading to secondary damage over time.
Other symptoms include:
- Firm, rounded bumps under the skin
- Thick, stiff, or dry skin
- Painless ulcers on the soles of the feet
- Swelling or lumps on the face or earlobes
- Loss of eyebrows or eyelashes
- Enlarged nerves near the elbows, knees, or sides of the neck
- Muscle weakness or paralysis in the hands and feet
Because the incubation period can stretch for years or even decades, many people don’t connect their symptoms to a possible exposure. The skin patches are easy to dismiss as a rash or dry skin, and the numbness develops so gradually it may not register as abnormal until significant nerve damage has already occurred.
Treatment Is Effective and Free
Leprosy has been curable since the 1980s with a combination of three antibiotics. The WHO provides this treatment free of charge worldwide. People with a milder form of the disease take the regimen for 6 months, while those with a more extensive infection take it for 12 months. Once treatment begins, a person quickly becomes noncontagious, often within days of starting.
The real problem is not treatment but timing. Nerve damage that occurs before diagnosis is often irreversible. The disabilities historically associated with leprosy, curled fingers, loss of feeling in the feet, facial changes, are consequences of late detection, not inevitable outcomes of the disease. When caught early, people recover fully with no lasting effects.
The Push Toward Elimination
The WHO’s global strategy for 2030 sets ambitious targets: 120 countries reporting zero locally acquired cases, a 70% reduction in new diagnoses overall, and a 90% reduction in new cases among children. The child case rate is considered especially important because it signals whether active transmission is being interrupted. With more than 9,000 children diagnosed in 2024, that goal still requires significant progress.
The biggest barriers are not medical but structural. Leprosy thrives in conditions of poverty and overcrowding, where people have limited access to healthcare and may live in close quarters for extended periods. Stigma also plays a major role. In many communities, a leprosy diagnosis still carries intense social consequences, which discourages people from seeking care until the disease has progressed far enough to cause visible disability. Breaking that cycle of stigma and late diagnosis is, at this point, a bigger challenge than the bacterium itself.